Brought to you by 
AZ pays $1.35bn up front for rights to Daiichi Sankyo's late-stage antibody-drug conjugate; deal could reach $6.9bn
27 Jul 2020
Executive Summary
AstraZeneca PLC paid a whopping $1.35bn up front for rights to co-develop and co-commercialize Daiichi Sankyo Co. Ltd.’s antibody-drug conjugate (Fam-) trastuzumab deruxtecan (DS8201). The up-front is the largest ever made by AstraZeneca for an in-licensed asset, and was paid for through a concurrent $3.5bn private placement.
Deal Industry
- Pharmaceuticals
-
Biotechnology
-
Large Molecule
- Antibodies
-
Large Molecule
Deal Status
- Final
Deal Type
-
Alliance
- Includes Royalty or Profit Split Information
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
AZ pays $1.35bn up front for rights to Daiichi Sankyo's late-stage antibody-drug conjugate; deal could reach $6.9bn
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice